Approval · Notice of Compliance 1319 · 2000
MENOMUNE: Notice of Compliance 1319
Issued April 26, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1319
- Date
- April 26, 2000
- Company
- Aventis Pasteur LimitedSwiftwater, Pennsylvania, United States
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Active immunizing agent
Products in this notice
Medicinal ingredients
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135 50 MCG per DOSE
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A 50 MCG per DOSE
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C 50 MCG per DOSE
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y 50 MCG per DOSE
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135 500 MCG per KIT
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A 500 MCG per KIT
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C 500 MCG per KIT
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y 500 MCG per KIT
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135 2.5 MG per KIT
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A 2.5 MG per KIT
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C 2.5 MG per KIT
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y 2.5 MG per KIT